《即日市評》恆指本周累升逾3% 匯控及藥明生物今受捧
美國去年12月通脹按年升6.5%符市場預期,按月跌0.1%(錄兩年半來首跌),市場料聯儲局下月加息0.25厘,港股今日反覆向上。美股道指及納指隔晚均升逾0.6%;執筆之時,美國10年期債券孳息率跌至3.43厘,美匯指數跌至102.04,道指期貨最新跌21點或0.06%,納指期貨最新跌0.11%。中國去年12月按美元計出口按年跌9.9%勝預期,去年12月按美元計進口按年跌7.5%(市場預期跌10%),上證綜指全日升31點或1%收3,195點,深證成指升1.2%,滬深兩市成交額7,023億人民幣。
恆指今日向上,大市高開90點後,早段曾跌39點一度低見21,474點,午後曾升255點一度高見21,770點,全日升224點或1%,收21,738點;國指升79點或1.1%,收7,391點;恆生科技指數67點或1.5%,收4,554點。大市全日成交總額1,330.11億元,滬、深港通南下交易淨流入17.35億及23.13億元人民幣。科網股今日走個別,騰訊(00700.HK)及阿里巴巴(09988.HK)股價各升2%及1.7%,但美團(03690.HK)跌1%。
恆指本周累升747點或3.6%、國指本周累升247點或3.5%、恆生科指本周累升123點或2.8%。美國早前公布上月非農業就業職位增幅多於市場預期,但平均時薪增長放緩,而美國昨晚公布上月通脹按年升6.5%符市場預期。
【港股反覆升 匯控有支持】
匯控(00005.HK)全日股價上揚2.6%收55.5元,今年以來股價持續向上及累升逾14%。中信証券本周初發表報告,首予匯控「增持」評級及目標價63元,相當於預測市賬率0.85倍,指匯控具備發達的全球佈局龐大客戶基礎,公司目前通過財富管理及個人銀行、工商金融、環球銀行及資本市場三大環球業務客戶提供多元化服,近年來公司積極推動增長優先引導的策略轉型,聚焦優勢區域,優化業務佈局,提高營運效率有望為公司注入新動能。
新東方在線(01797.HK)全日股價彈高15.2%。據內媒《銀柿財經》引述消息報道,今年內地春晚主會場直播的合作方將是新東方在線(01797.HK)旗下東方甄選,報道指該公司簽約主播董宇輝已在彩排。
【升股千一隻 藥明生物彈】
港股今日市寬改善,主板股票的升跌比率為28比13(上日19為比21),上升股份1,195隻(升幅3.2%);恆指成份股今日52隻股份上升,下跌股份19隻,升跌比率為68比25(上日為67比30);大市今日錄沽空226.31億元,佔可沽空股份成交額1,192.12億元的18.984%(上日為17.912%)。
藥明康德(02359.HK)全日股價上揚近3.6%,藥明生物(02269.HK)股價彈高6.4%收72.6元。高盛發表報告指,藥明生物管理層日前在電話會議上透露今年收入增長指引維持30%以上,預期非新冠相關業務收入增長可達60%,而新冠業務則輕微減少。管理層又提到歐洲(按年增80%)、日本/韓國(按年增100%)市場增長強,中國市場則略為轉弱。
考慮到非新冠相關業務收入下降,高盛將藥明生物今年每股盈利預測下調1.5%,基於五年退出期的預測市盈率,維持藥明生物目標價93元不變,評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.